Form D · Biotechnology

Bell Biosystems, Inc.

San Francisco, CA · CIK 0001550379

Offering snapshot reported Apr 13, 2015 · SEC filing

Reported sold: $3.81M
Investors reported: 25
Minimum accepted: $0
First sale: Dec 23, 2013

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$2,058,230 → $3,810,250
Reported investors20 → 25

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Apr 13, 2015	Amendment	$3,810,250	$1,752,020vs Jan 8, 2014	25	SEC filing
Jan 8, 2014	Initial	$2,058,230	No comparison	20	SEC filing
May 31, 2012	Initial	$250,000	No comparison	3	SEC filing
May 31, 2012	Initial	$120,000	No comparison	9	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-209484

Series A Preferred Stock (Total Amount Sold includes conversion of Convertible Promissory Notes).

Source: Form D, filed Apr 13, 2015. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Caleb B. Bell	Director, Executive
Daniel Bell	Executive
Stuart Berman	Director
Bell B. Caleb	Director, Executive
Bell, Iii B. Caleb	Director, Executive
Christian Olgaard	Director
Una Ryan	Director
Gil Van Bokkelen	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

953 Indiana Street
San Francisco, CA, 94107